271 related articles for article (PubMed ID: 33955826)
1. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract][Full Text] [Related]
2. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract][Full Text] [Related]
3. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract][Full Text] [Related]
5. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
6. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
7. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
8. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
10. Genomic Instability Promotes the Progression of Clear Cell Renal Cell Carcinoma Through Influencing the Immune Microenvironment.
Wei X; Wang Y; Ji C; Luan J; Yao L; Zhang X; Wang S; Yao B; Qin C; Song N
Front Genet; 2021; 12():706661. PubMed ID: 34712264
[No Abstract] [Full Text] [Related]
11. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response.
Su Y; Zhang T; Lu J; Qian L; Fei Y; Zhang L; Fan S; Zhou J; Tang J; Chen H; Liang C
Cells; 2023 Jan; 12(1):. PubMed ID: 36611973
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
Front Immunol; 2022; 13():861328. PubMed ID: 35479084
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
18. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
Front Immunol; 2022; 13():869297. PubMed ID: 35936012
[TBL] [Abstract][Full Text] [Related]
20. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]